AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Thursday 12 November 2026
News from the 24 hours to Thursday morning, 12 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was dominated by the acquisition of vaccine start-up Omniose, which was seen as strengthening its bacterial vaccine pipeline. Analyst target increases after third-quarter results, oncology growth and a UAE approval added to the positive lean, with only a mixed FDA panel outcome tempering it.
What drove it
- Omniose acquisition
- analyst target upgrades
- oncology growth
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Fri 6 Nov | +4.0 | 37 |
| Sat 7 Nov | +4.5 | 9 |
| Sun 8 Nov | +6.0 | 7 |
| Mon 9 Nov | +5.3 | 4 |
| Tue 10 Nov | +5.5 | 12 |
| Wed 11 Nov | +6.3 | 22 |
| Thu 12 Nov | +7.5 | 25 |
| Fri 13 Nov | +5.3 | 8 |
9 stories · 25 headlines · strongest first
Pharma and healthcare on 12 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca acquires US biotech Omniose +7.411 headlines today · 21 in all, since 11 November · Many outlets report AstraZeneca bought vaccine startup Omniose. | ||
| +8.3 | Bolt-on deal strengthens bacterial vaccine work. | |
| +8.3 | Deal reinforces bacterial vaccine pipeline. | |
| +8.3 | Vaccine start-up purchase adds pipeline strength. | |
| +8.3 | Gains a bioconjugation platform for vaccines. | |
| +8.3 | Purchase offers simpler route to manufacture conjugate vaccines. | |
| +8.3 | Acquisition aids vaccines against serious bacterial infections. | |
| +8.3 | Acquisition expands its infectious disease and vaccine capabilities. | |
| +8.0 | Takeover of local vaccine start-up. | |
| +8.0 | Deal for a vaccine developer adds capability. | |
| +8.0 | Buys vaccine technology firm. | |
| +5.0 | Vaccine acquisition, alongside a sector-wide safety warning. | |
| AstraZeneca analyst target changes and guidance +6.86 headlines today · 8 in all, since 11 November · Nine out of ten analyst firms increased their price targets for AstraZeneca after Q3, and coverage of the results carried on. | ||
| +10.0 | Broad analyst target increases after quarterly results. | |
| +10.0 | Most analyst houses lifted targets after quarter. | |
| +8.3 | Core earnings rising again after results. | |
| +7.5 | Specialty medicines supporting growth despite pressures. | |
| +6.7 | Cancer franchise growth more than offsets a declining product. | |
| +5.8 | Quarterly growth and outlook, with a win and setbacks. | |
| AstraZeneca share price technical and quote pieces +0.22 headlines today · 3 in all · Pieces cover the share price near GBX13,821 and a 13,896.0p quote. | ||
| +0.5 | Share price barely changed on the day. | |
| 0.0 | Shares trading sideways near support level. | |
| UAE gives first conditional approval to AstraZeneca's Berger's disease drug +9.21 headline today · The UAE is the first nation to give the drug conditional approval. | ||
| +9.2 | First conditional approval for kidney disease drug. | |
| AstraZeneca sector screener pick +7.51 headline today · A screener piece gives reasons to back AstraZeneca. | ||
| +7.5 | Screener sees case for recovery in the shares. | |
| AstraZeneca oncology launches +6.71 headline today · A piece asks whether AstraZeneca is scaling oncology launches. | ||
| +6.7 | Question over progress of cancer drug launches, leaning positive. | |
| AstraZeneca reportedly bids $10bn for Rhythm Pharmaceuticals +3.81 headline today · 39 in all, since 5 November · A piece links the reported Rhythm bid to Palatin's obesity pipeline. | ||
| +5.0 | Reported large bid signals ambition in obesity. | |
| AstraZeneca awards $1.6m for US healthcare access programmes +4.21 headline today · 2 in all, since 11 November · AstraZeneca gave $1.6m in grants to 55 nonprofits. | ||
| +5.0 | Community grants give modest reputational benefit. | |
| FDA panel gives mixed outcome on AstraZeneca cancer drugs −1.71 headline today · 2 in all · An FDA panel gave mixed outcomes on cancer drugs. | ||
| −1.7 | Regulatory panel gave split verdicts on cancer drugs. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.